Flow cytometry assay of myeloid dendritic cells (mDCs) in peripheral blood during acute hepatitis C: possible pathogenetic mechanisms.
OBJECTIVE
To asses the expression of myeloid dendritic cells (CD11c+) subset during acute HCV hepatitis and its possible involvement in natural history of the infection.


METHODS
We enrolled 11 patients with acute hepatitis C (AHC) (Group A), 10 patients with acute hepatitis A (AHA) (as infective control-Group B) and 10 healthy donors (group C) in this study. All patients underwent selective flow cytometry gating strategies to assess the peripheral number of the myeloid dendritic cells (mDCs) to understand the possible role and differences during acute hepatitis.


RESULTS
Eight of 11 patients with acute HCV hepatitis did not show any increase of mDCs compared to healthy individuals, while a significant decrease of mDCs was found in absolute cell count (z = -2.37; P<0.05) and percentage (z = -2.30; P<0.05) as compared with AHA. On the contrary, The remaining three patients of the group A had a higher mDCs number and percentage as occur in group B. Interestingly, after six months, those patients did not show any increase of mDCs subset were chronically infected. while the three subjects with an increase of peripheral mDCs, as in HAV acute infection, resolved the illness.


CONCLUSIONS
The lack of increase of mDCs during acute hepatitis C might be an important factor involved in chronicization of the infection.
Perrella
Alessandro
A
Department Infectious Disease and Immunology, Hospital D.Cotugno, Via E.A. Mario 35 , Zip code 80131, Naples, Italy. alex.perrel@virgilio.it
Atripaldi
Luigi
L
Bellopede
Pasquale
P
Patarino
Tommaso
T
Sbreglia
Costanza
C
Tarantino
Giovanni
G
Sorrentino
Paolo
P
Conca
Paolo
P
Ruggiero
Luca
L
Perrella
Oreste
O
D000208:Acute Disease; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D018845:CD11 Antigens / Q000032:analysis; D016022:Case-Control Studies; D002452:Cell Count; D003713:Dendritic Cells / Q000276:immunology; D018450:Disease Progression; D004338:Drug Combinations; D005260:Female; D005434:Flow Cytometry; D006506:Hepatitis A / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000276:immunology; D006526:Hepatitis C / Q000097:blood* / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D018950:Lipopolysaccharide Receptors / Q000032:analysis; D008297:Male; D008875:Middle Aged; D022423:Myeloid Cells / Q000276:immunology; D012254:Ribavirin / Q000627:therapeutic use
D000998:Antiviral Agents; D018845:CD11 Antigens; D004338:Drug Combinations; D018950:Lipopolysaccharide Receptors; D012254:Ribavirin; D007372:Interferons